AUTHORS
Kaylyn Utley Lyons, MD, Lucy E. Cain, MBBS FRACP2, Amanda DiNofia, MD3, Allison Barz Leahy, MD MSCE4, Shannon L. Maude, MD5, Stephan A Grupp, MD, PhD6, Regina M. Myers, MD7
AFFILIATIONS
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Background
The TCF3::PBX1 fusion, resulting from translocation t(1;19)(q23;p13), defines a rare molecular subtype of pediatric B-lymphoblastic leukemia/lymphoma (B-ALL/B-LLy). Although this subtype is considered standard risk at diagnosis, outcomes after relapse are poor with a marked propensity for central nervous system (CNS) and other extramedullary disease (EMD) relapse. The impact of this distinct relapse pattern on outcomes following chimeric antigen receptor T-cell therapy (CART) warrants investigation.
Objective
To define clinical outcomes following CART in children and young adults with relapsed or refractory (r/r) TCF3::PBX1 B-ALL/B-LLy.
Methods
We retrospectively identified children and young adults <30 years of age with r/r TCF3::PBX1 B-ALL/B-LLy treated with murine or humanized CD19- or CD22-directed CART across seven clinical trials or with commercial tisagenlecleucel at Children's Hospital of Philadelphia. Patients were analyzed in two cohorts: CAR-naïve and CAR-retreatment. The primary outcome was event-free survival (EFS). Secondary outcomes included complete remission (CR) rate and overall survival (OS).
Results
Twenty-one CART treatments administered to 20 patients were included, comprising 14 CAR-naïve and 7 CAR retreatment patients. One CAR-naïve patient was treated for B-LLy; all remaining patients had B-ALL. Patients underwent retreatment for relapse (n=6) or early B-cell recovery (BCR; <6 months) (n=1). Among CAR-naïve patients, 9/14 (64%) received CART in first relapse, whereas 5/7 (71%) retreatment patients were treated in second relapse. In the CAR-naïve cohort, 13/14 (93%) received CD19-directed CART and 1/14 (7%) received CD22-directed CART. In the retreatment cohort, 4/7 (57%) received CD22-directed CART, 2/7 (29%) CD19-directed CART, and 1/7 (14%) received CD19/CD22 CART co-infusion. Pre-infusion high disease burden (≥25% marrow blasts) was common in both cohorts (9/14 [64%] and 5/7 [71%], respectively). Non-CNS EMD was present at infusion in 4/14 (29%) CAR-naïve and 3/7 (43%) retreatment patients. One CAR-naïve patient had isolated CNS2 disease, while one retreatment patient had concomitant CNS3 and non-CNS EMD.
Among 13 evaluable CAR-naïve patients assessed for response on day 28, 9 (69%) achieved a measurable residual disease-negative complete remission (CR) compared with 4/7 (57%) retreatment patients. All four CAR-naïve patients with non-CNS EMD failed to achieve a CR and experienced concurrent marrow progression. In the retreatment cohort, one of three patients with non-CNS EMD achieved CR, while two experienced simultaneous marrow and EMD progression. Early BCR occurred in two CAR-naïve patients: one promptly relapsed, and the other underwent CAR retreatment for this indication.
Among CAR-naïve patients, 13/14 (93%) experienced cytokine release syndrome (CRS), including five grade ≥3 events, and 6/14 (43%) developed neurotoxicity, including one grade ≥3 event. Among retreatment patients, 4/7 (57%) experienced CRS, including one grade ≥3 event, and no neurotoxicity was observed.
With a median follow-up of 46 months, CAR-naïve patients had a median EFS of 6 months, with an estimated 2-year EFS and OS of 12% (95% CI, 5–40%) and 19% (95% CI, 3–45%), respectively. Among retreatment patients, the median follow-up was 17 months with a median EFS of 4 months and estimated 2-year EFS and OS of 29% (95% CI, 4–61%) and 29% (95% CI, 1-69%), respectively. All patients with EMD ultimately experienced progressive disease or relapse. Conversely, all patients with disease burden ≤5% at infusion were alive at last follow-up. The only long-term survivor infused with ≥25% marrow disease experienced a morphologic relapse but subsequently achieved remission following consolidative hematopoietic stem cell transplant.
Conclusions
Children and young adults with TCF3::PBX1 B-ALL/B-LLy experienced lower remission rates and markedly inferior survival following CAR T-cell therapy than reported in historical pediatric cohorts. Although this population was enriched for patients with high marrow disease burden at infusion, non-CNS extramedullary disease identified an exceptionally high-risk subgroup characterized by primary CAR resistance and universal treatment failure. Larger multi-institutional studies are needed to define outcomes in TCF3::PBX1 B-ALL/B-LLy and to better understand the biology and optimal management of extramedullary disease in this subtype.
DISCLOSURES
Kaylyn Utley Lyons, MD: No relevant conflicts of interest to declare.